Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ImmunoPrecise Antibodies

IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
IPA to Present at Jefferies Healthcare Conference 2023
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
From ImmunoPrecise Antibodies
Via Business Wire
Tickers BCTX BCTXW IPA TSX:BCT
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA TSX-V:IPA
Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA TSX-V:IPA
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA TSX-V:IPA
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA TSX-V:IPA
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA TSX-V:IPA
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA TSX-V:IPA
IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
Preclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease
From ImmunoPrecise Antibodies
Via Business Wire
Tickers IPA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.